Friday, December 27, 2013
Wednesday, December 25, 2013
- Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development
- Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods
- A Time to Event Tutorial for Pharmacometricians
- Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance
Happy Holidays!Video recordings and lecture notes from six semester-long courses (MI205, MI210, MI212, MI250, MI255, and MI260) can be found on the Metrum Institute YouTube channel (http://www.youtube.com/metruminst). Topics include: R programming for pharmacometrics, introductory and intermediate topics in population PK modeling, modeling continuous and categorical population PKPD data, Bayesian PKPD modeling, and Bayesian model-based meta-analysis.
Saturday, June 15, 2013
Tuesday, June 16, 2009
Information gathered during these studies include PK parameters such as area under the curve (AUC, exposure), Cmax (maximum concentration) , Tmax (Time to Cmax), half life, clearance, volume of distribution, bioavailability, steady state plasma concentrations, accumulation ratio, linear or nonlinear PK, time dependent PK (auto-induction), plasma protein binding, metabolite identity and their PK.
Here goes the list.
1. Single Ascending Dose (SAD)I will be blogging on each of these topics in the next few weeks. I am quite keen to know how modeling & simulation approaches have been used in early clinical PK studies. Feel free to share your thoughts/comments, any unusual experiences in the conduct of these studies.
2. Multiple Ascending Dose (MAD)
3. Food Effect Studies
4. ADME Mass Balance Studies
5. Absolute/Relative Bioavailability
6. Thorough QTc Study
7. Drug Interaction Studies - Enzyme Inhibition/Induction
8. Effect of Age and Gender
9. Special Population - Hepatic Impairment
10. Special Populaiton - Renal Impairment
11. Impact of Genetic Polymorphisms of Drug Metabolizing Enzymes
Tuesday, June 9, 2009
All the methods and procedures for bioAMS were developed at Lawrence Livermore National Lab (LLNL) and the latest technology, the BioMICADAS developed by ETH/Zwitzerland and Vitalea Science (who has the original developer of bioAMS). It is important that people know the history of bioAMS and that it was the results of 15 years of intense research at Livermore in genotoxicity, nutrition, chemical interactions, pharmacology, and enviornmental studies. Other companies simply transferred some of the methods from LLNL.
What needs to be understood is that AMS is much more than Phase 0. As a CRO, many companies are doing microdosing as a means of "understanding the physiochemistry" of their compounds. The predictive PK topic is not the primary objective of microdosing, as PK can be solved later in formulation development. Microdosing is early ADME and understanding of the human metabolism. Receptor binding, tissue biopsies, cell loading, routes of elimination, protein binding, biotransformation, etc...can all be ascertained in a microdosing study. This indeed is what the specificity of a tracer and the sensitivity of AMS uncover.
There is a growing body of evidence that microdosing is predictive of macrodose PK, but again, that is not our (Vitalea's) principal focus nor would it be if I were a drug developer. Rank ordering multiple candidates is an interesting idea to supplant animal testing and I am surprised it is not used more, but generally developers are pretty attached to "their" candidate - thus we see scientists simply want to learn more so that they can have more efficient later Phase trials with fewer surprises. Analyses that we have been asked to do in microdosing proper are
- Prodrug metabolism
- Cellular penetration (Cell Loading)
- Confirm absence or presence of unwanted metabolites
- Potential for protein binding
- Balance (does the drug come out).
I think this last point is important, as one will never see deep reservoirs with macrodose ADME clearly. We have seen drug material leak out for weeks in some cases for a 6 hr half-life drug. None of it is parent drug. When these drugs become daily doses, these reservoirs accumulate and essentially lead to self-drugging by the drug and its metabolites. The impact this could have on idiosyncratic adverse events and safety in general, is real, and should be known in advance. Macrodoses swamp the system and tell little of the PhysioKemistry that is alway active, but not perceptible.
It is everyone’s desire to find a panacea to the complexity of drug development. Perhaps that is unrealistic. I see a new age where companies spend more time on their molecules, understanding and viewing metabolism and PhysioKemistry not as a nuisance, but as a tool to understand the drug fully (or class of compounds) avoid the potential for later stage surprises, and streamline IND phase testing once it commences.
The marginal relevance of animal testing is clear despite the objections of the preclin crowd (no disrespect here) - how can sub-therapeutical human data not be valuable in myriad ways. That is the question to be asked? Not is microdosing predictive of macrodose PK. Pharmacokinetic prediction is great, but metabolism impacts safety in unexpected ways. Microdosing or Phase 1 ADME using microtracers is a very good option to make better decisions.The hot topic is now MIST guidance, not so much Phase 0. AMS finds all metabolites without method development or internal standards.
Just coming back from ASMS, it is clear that MIST guidance has put a good deal of "concern" into the pharma business about how to address this important safety issue of steady state metabolite exposure. While my head is still trying to sort through the myriad configurations of hybridized MS instrumentation, the common theme running through all the very excellent MS talks was that radioanalysis is the most straightforward and absolute means of addressing MIST. Non-traditional radioanalysis, using AMS, expedites the entire endeavor.
It would appear that the field has come full circle - nothing is so powerful as a near 0 background analysis (14C) for unequivocal metabolite discovery, After discovery, one would then need to enlist the many sophisticated and quite impressive MS techniques for metaID when odd metabolites are revealed.
I do not see PK as the most important issue. Safety and Efficacy are the issue, and PhysioKemistry provides a view into processes that impact the later. This is a complex business. I am not sure if "more shots on goal" by emphasizing speed over understanding is the way to go.
Feel free to discuss and share your experience with Microdosing/AMS/Microtracer studies.
Thursday, April 30, 2009
Have fun learning!
Monday, December 15, 2008
Listed below are some guidances where PopPK or PK/PD studies are recommended by FDA or EMEA.
Population Pharmacokinetics [PDF] - This document provides recommendation on the study design and execution, model development & validation and reporting the results of a PopPK analysis. Some examples of how the results are used in drug labeling are also provided. However, the document doesnt delve deep into the qualification of softwares used for such analysis. Neither does it talk about any preferred softwares like NONMEM or SAS or Splus.
Guideline on Reporting the Results of Population Pharmacokinetic Analysis [PDF] - This EMEA guideline provides in detail the information required in a report submitted for their review. I like this document over FDA's guidance especially because they spell out exactly the kind of information one needs to report in terms of NONMEM lingo eg, choice of analysis (parametric or non parametric or bayesian), estimation methods (FO vs FOCE vs FOCE INTER), GOF plots like DV vs PRED, DV vs IPRED (with line of identity and trend line (:>)) and so forth.
Other guidances that recommend PK/PD evaluations include
- FDA Final Guidance on exposure-response relationships - study design, data analysis and regulatory applications. [PDF]
- Pharmacokinetics in Pregnancy— Study Design, Data Analysis, and Impact on Dosing and Labeling [PDF] -
- Guideline on the Role of Pharmacokinetics in the Development of Medicinal Products in the Paediatric Population [PDF] - Efficay and safety data from adults can be extrapolated to obtain PK information for paediatric patients. When PK studies are to be carried out in paediatric population, PopPK studies with sparse sampling methodolgy seems to be the best approach. In young patients, there is rapid maturation of organs that are involved in drug absorption, distribution and elimination necessiating different dosage regimen. Thus for drugs that are intended to be used in paediatrics, this document provides recommendations on the study design of PK studies.
More in my next post...
Friday, November 14, 2008
Monday, November 3, 2008
Ok. My main objective of this post was to share some resources that are available to learn model data using NONMEM. In addition to the above discussion group, I have learnt immensely from the following resources.
a. Resources by Nick Holford: These course materials are freely available with enough background information to start performing population PKPD analysis.
b.Resource Facility for Population Pharmacokinetics[RFPK] – When accessing this site, you will have to fill a short questionnaire before downloading or viewing the tutorials/ presentations.
c. Nonlinear mixed effect models: an overview and update [PDF]
d. Laboratory of Applied Pharmacokinetics (LAPK) teaching resources by Roger Jeliffe.
- New Advances in PK/PD Modeling [PDF]
- Pop PK: Parametric & Non parametric Approaches [PDF]
- Bayes Theorem and Other PK resources [PDF]
f. Regulatory Guidances
- US FDA Population Pharmacokinetics [PDF]
- EMEA Guideline on Reporting the Results of Population Pharmacokinetic Analyses [PDF]
If you know of more resources that can be added to this list, please feel free to provide the information by way of comments. Good night!